Consensus Figures
Analysts' consensus Q1 2019 and FY 2019 as at 15 April 2019
| Q1 2018 | FY 2018 | Q1 2019 E* | FY 2019 E* | |
|---|---|---|---|---|
| Sales (continuing) | ||||
| Number of Estimates | 16 | 17 | ||
| Highest | 2,486 | 9,564 | ||
| Consensus | 2,435 | 9,267 | 2,297 | 9,331 |
| Median | 2,273 | 9,343 | ||
| Lowest | 2,229 | 9,010 | ||
| adj. EBITDA (continuing) | ||||
| Number of Estimates | 16 | 17 | ||
| Highest | 409 | 1,727 | ||
| Consensus | 538 | 1,822 | 397 | 1,665 |
| Median | 394 | 1,660 | ||
| Lowest | 383 | 1,629 | ||
| of which estimated adj. EBITDA from"Temporary Vitamin Effect" | ||||
| Number of Estimates | 11 | 12 | ||
| Highest | 0 | 0 | ||
| Consensus | 165 | 290 | 0 | 0 |
| Median | 0 | 0 | ||
| Lowest | 0 | 0 | ||
| Underlying business, adj. EBITDA | ||||
| Number of Estimates | 16 | 17 | ||
| Highest | 409 | 1,727 | ||
| Consensus | 373 | 1,532 | 397 | 1,665 |
| Median | 394 | 1,660 | ||
| Lowest | 383 | 1,629 | ||
| adj. EBIT (continuing) | ||||
| Number of Estimates | 13 | 16 | ||
| Highest | 280 | 1,189 | ||
| Consensus | 423 | 1,345 | 268 | 1,140 |
| Median | 265 | 1,139 | ||
| Lowest | 259 | 1,091 | ||
| Nutrition, Sales | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | 1,650 | 6,137 | 1,699 | 6,385 |
| Consensus | 1,514 | 6,148 | ||
| Median | 1,495 | 6,136 | ||
| Lowest | 1,448 | 5,906 | ||
| Nutrition, adj. EBITDA | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | 442 | 1,407 | 311 | 1,289 |
| Consensus | 298 | 1,240 | ||
| Median | 299 | 1,240 | ||
| Lowest | 285 | 1,197 | ||
| of which adj. EBITDA from"Temporary Vitamin Effect" | ||||
| Number of Estimates | 11 | 11 | ||
| Highest | 165 | 290 | 0 | 0 |
| Consensus | 0 | 0 | ||
| Median | 0 | 0 | ||
| Lowest | 0 | 0 | ||
| Nutrition underlying, adj. EBITDA | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | 277 | 1,117 | 311 | 1,289 |
| Consensus | 298 | 1,240 | ||
| Median | 299 | 1,240 | ||
| Lowest | 285 | 1,197 | ||
| Nutrition, adj. EBIT | ||||
| Number of Estimates | 12 | 13 | ||
| Highest | 370 | 1,111 | 233 | 969 |
| Consensus | 219 | 915 | ||
| Median | 219 | 915 | ||
| Lowest | 210 | 863 | ||
| Materials, Sales | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | 738 | 2,913 | 766 | 3,042 |
| Consensus | 735 | 2,960 | ||
| Median | 738 | 2,965 | ||
| Lowest | 701 | 2,876 | ||
| Materials, adj. EBITDA | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | 126 | 512 | 128 | 545 |
| Consensus | 123 | 518 | ||
| Median | 125 | 516 | ||
| Lowest | 117 | 501 | ||
| Materials, adj. EBIT | ||||
| Number of Estimates | 12 | 13 | ||
| Highest | 95 | 383 | 96 | 428 |
| Consensus | 89 | 380 | ||
| Median | 90 | 379 | ||
| Lowest | 79 | 331 | ||
| Innovation Center, Sales | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | 36 | 172 | 47 | 191 |
| Consensus | 40 | 181 | ||
| Median | 39 | 180 | ||
| Lowest | 36 | 172 | ||
| Innovation Center, adj. EBITDA | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | -1 | 8 | 5 | 32 |
| Consensus | 2 | 14 | ||
| Median | 3 | 13 | ||
| Lowest | -1 | 5 | ||
| Innovation Center, adj. EBIT | ||||
| Number of Estimates | 12 | 13 | ||
| Highest | -6 | -14 | -2 | -9 |
| Consensus | -4 | -14 | ||
| Median | -4 | -11 | ||
| Lowest | -9 | -32 | ||
| Corporate Activities, Sales | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | 11 | 45 | 18 | 70 |
| Consensus | 12 | 48 | ||
| Median | 11 | 46 | ||
| Lowest | 10 | 45 | ||
| Corporate Activities, adj. EBITDA | ||||
| Number of Estimates | 15 | 15 | ||
| Highest | -29 | -105 | -25 | -95 |
| Consensus | -27 | -106 | ||
| Median | -27 | -106 | ||
| Lowest | -29 | -110 | ||
| Corporate Activities, adj. EBIT | ||||
| Number of Estimates | 12 | 13 | ||
| Highest | -36 | -135 | -32 | -133 |
| Consensus | -35 | -138 | ||
| Median | -35 | -138 | ||
| Lowest | -37 | -145 | ||
| Profit for the period, before exceptional items - Cont. Ops. | ||||
| Number of Estimates | 12 | 14 | ||
| Highest | 337 | 1,034 | 217 | 923 |
| Consensus | 204 | 863 | ||
| Median | 205 | 865 | ||
| Lowest | 191 | 813 | ||
| Net EPS before exceptional items - Cont. Ops. | ||||
| Number of Estimates | 12 | 14 | ||
| Highest | 1.91 | 5.84 | 1.25 | 5.30 |
| Consensus | 1.16 | 5.00 | ||
| Median | 1.16 | 5.00 | ||
| Lowest | 0.72 | 1.08 | 4.71 |
北京快3线路 www.4w1e.cn * Analysts were asked by Vara Research to include the estimated IFRS16 effect in the DSM consensus poll for 2019 Q1 and FY 2019.
Disclaimer
Consensus earnings estimates are based on earnings projections made by securities analysts who cover DSM. Any opinions, forecasts, estimates, projections or predictions regarding DSM’s performance made by the analysts (and, therefore, the Consensus estimate numbers) are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of DSM or its management. DSM does not by providing these estimates imply its endorsement of or concurrence with such information, conclusions or recommendations. DSM assumes no liability for the accuracy of such estimates and undertakes no obligation to update or revise such estimates.
